Skip to main navigation
Ascendis Pharma Logo
  • Overview
  • Events & Presentations
  • News Releases
    • For Global Media Only
    • For U.S. Media Only
  • Corporate Governance
    • Corporate Governance Documents & Charters
    • Leadership
    • Committee Composition
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Financial & Filings
    • Quarterly Reports
    • SEC Filings
    • Annual General Meeting
    • Extraordinary General Meeting
      • Sept. 9, 2022 EGM
      • Nov. 18, 2021 EGM

News Releases
Intended for U.S. Media Only

News Releases

March 10, 2023
Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
February 16, 2023
Ascendis Pharma Reports Full Year 2022 Results
February 7, 2023
Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
January 8, 2023
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
January 3, 2023
Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Shareholder Tools

RSS Feeds
Email Alerts
IR Contact

Footer Corporate Menu

  • TransCon
  • About us
  • Pipeline
  • Patients
  • Investors & News
  • Contact Us

Footer Copyrights Menu

  • Privacy Policy
  • Terms of Use
Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group
© March 2023 Ascendis Pharma